What is the 13F Pro Quality Score for IMRX?

13F Pro ranks Immuneering Corp (IMRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IMRX's current score at https://13fpro.ai/research/IMRX (free sign-up required for the full ranking).

Which hedge funds own the most IMRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IMRX include FMR, Sanofi, MARSHALL WACE, LLP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/IMRX as soon as new 13F filings post.

Where does 13F Pro source IMRX data?

All Immuneering Corp fundamentals and ownership data come directly from SEC EDGAR. Immuneering Corp files with the SEC under CIK 1790340. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IMRX in?

Immuneering Corp (IMRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IMRX research updated on 13F Pro?

IMRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Immuneering Corp(IMRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1790340 IMRX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $2.3M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

IMRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Immuneering Corp (IMRX), a Healthcare sector company. IMRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $2.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), Immuneering Corp reports net income of $-13.5M, free cash flow of $-18.5M. Top institutional holders of IMRX by reported 13-F value include FMR, Sanofi, MARSHALL WACE, LLP, based on the most recent SEC filings. IMRX trades on the Nasdaq exchange and files with the SEC under CIK 1790340. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immuneering Corp directly from SEC EDGAR.

Net Income

Q1 2026

$-13.5M

Free Cash Flow

Q1 2026

$-18.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY21 $2.1MFY22 $317.0KFY24 —FY25 —

Net Income

+8.2% YoY

$-56.0MFY 2025

FY21 $-33.5MFY22 $-50.5MFY24 $-61.0MFY25 $-56.0M

Operating Income

+7.3% YoY

$-59.4MFY 2025

FY21 $-33.9MFY22 $-51.7MFY24 $-64.1MFY25 $-59.4M

EPS (Diluted)

+37.7% YoY

$-1.27FY 2025

FY21 $-2.46FY22 $-1.91FY24 $-2.04FY25 $-1.27

Total Assets

+340.1% YoY

$232.0MFY 2025

FY21 $166.7MFY22 $122.4MFY24 $52.7MFY25 $232.0M

Op. Cash Flow

+17.6% YoY

$-45.3MFY 2025

FY21 $-30.9MFY22 $-44.1MFY24 $-55.0MFY25 $-45.3M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Revenue	—	—	$317.0K -84.8%	$2.1M -10.0%	$2.3M
Net Income	$-56.0M +8.2%	$-61.0M -20.8%	$-50.5M -50.6%	$-33.5M -96.8%	$-17.0M
Operating Income	$-59.4M +7.3%	$-64.1M -23.8%	$-51.7M -52.7%	$-33.9M -98.4%	$-17.1M
EPS (Diluted)	$-1.27 +37.7%	$-2.04 -6.8%	$-1.91 +22.4%	$-2.46 +28.5%	$-3.44
Total Assets	$232.0M +340.1%	$52.7M -56.9%	$122.4M -26.6%	$166.7M +333.9%	$38.4M
Operating Cash Flow	$-45.3M +17.6%	$-55.0M -24.7%	$-44.1M -42.9%	$-30.9M -111.0%	$-14.6M

AI Insight: IMRX Financial Trends

Pre-revenue biotech burning $12–18M quarterly with equity nearly flat despite $189M cash infusion in Q3 2025.

• Net loss stabilized at $12–15M/quarter in recent periods after peaking at $18M in Q4 2024.

• Operating cash burn improved to $9M in Q2 2025 but deteriorated to $18M in Q1 2026.

• Equity surged from $29M (Q2 2025) to $228M (Q3 2025), signaling capital raise, then declined to $207M by Q1 2026.

⚠ Operating cash burn worsened to $18M in latest quarter—highest since Q4 2024. Runway at risk.

⚠ No revenue visible across entire period. Clinical-stage execution and trial advancement critical.

AI Insight: IMRX Ratio Trends

Immuneering's return metrics collapsed through mid-2025, then stabilized at deeply negative levels; profitability remains elusive.

• ROE deteriorated from -84.9% in Q2 2024 to -199.5% in Q2 2025, then recovered sharply to -26.1% in Q1 2026.

• ROA and ROIC show similar V-shaped pattern: ROA bottomed at -85.2% in Q3 2024, recovered to -25.1% in Q1 2026.

⚠ Company remains unprofitable across all periods; no margin data available indicates ongoing pre-commercialization or development stage.

⚠ Latest quarter (Q1 2026) ROE/ROA/ROIC stabilized ~25–30% negative but remain far from acceptable returns; inflection timing uncertain.

Get alerted when IMRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Immuneering Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IMRX

FMR LLC
$51.1M9,697,938 sh
Sanofi
$14.3M2,708,559 sh
MARSHALL WACE, LLP
$10.5M1,996,585 sh
BlackRock, Inc.
$7.9M1,507,258 sh
MILLENNIUM MANAGEMENT LLC
$5.8M1,102,712 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.4M637,944 sh
Occam Crest Management LP
$2.9M545,098 sh
CITADEL ADVISORS LLC
$2.4M447,278 sh
Connor, Clark & Lunn Investment Management Ltd.
$2.1M400,363 sh
Summit Financial, LLC
$2.0M376,749 sh

Fund	Value	Shares
FMR LLC	$51.1M	9,697,938
Sanofi	$14.3M	2,708,559
MARSHALL WACE, LLP	$10.5M	1,996,585
BlackRock, Inc.	$7.9M	1,507,258
MILLENNIUM MANAGEMENT LLC	$5.8M	1,102,712
GEODE CAPITAL MANAGEMENT, LLC	$3.4M	637,944
Occam Crest Management LP	$2.9M	545,098
CITADEL ADVISORS LLC	$2.4M	447,278
Connor, Clark & Lunn Investment Management Ltd.	$2.1M	400,363
Summit Financial, LLC	$2.0M	376,749

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IMRX on your watchlist

Track score changes the day Immuneering Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IMRX a good stock to buy?

13F Pro's AI-powered analysis of Immuneering Corp (IMRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMRX are available on the IMRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IMRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Immuneering Corp's investment landscape.